



# The Director

of the United States Patent and Trademark Office has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, shis United States

# atent

grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.

Om Halfell

Performing the Functions and Duties of the Under Secretary of Commerce for Intellectual Property and

Director of the United States Patent and Trademark Office



### US011058718B2

# (12) United States Patent Kubota et al.

# (54) METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITH THE COMBINATION OF POLAPREZINC AND SODIUM SELENITE

(71) Applicant: Medico Consl Co., Ltd., Osaka (JP)

(72) Inventors: **Satoru Kubota**, Osaka (JP); **Toru Kono**, Hokkaido (JP)

(73) Assignee: MEDICO CONSL CO., LTD., Suita

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 16/892,728

(22) Filed: Jun. 4, 2020

(65) Prior Publication Data

US 2020/0405754 A1 Dec. 31, 2020

# Related U.S. Application Data

- (63) Continuation-in-part of application No. 16/473,888, filed on Jun. 26, 2019, now abandoned.
- (51) Int. Cl.

  A61K 33/30 (2006.01)

  A61P 1/16 (2006.01)

  A61K 33/04 (2006.01)

(52) U.S. Cl. CPC ....... A61K 33/30 (2013.01); A61K 33/04 (2013.01); A61P 1/16 (2018.01)

(56) References Cited

# **PUBLICATIONS**

Sugino (Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis, Journal of Gastroenterology and Hepatology 23, 2008, pp. 1909-1916).\*

(10) Patent No.: US 11,058,718 B2

(45) Date of Patent:

Jul. 13, 2021

Ming Ding (Selenium Supplementation Decreases Hepatic Fibrosis in Mice After Chronic Carbon Tetrachloride Administration, Biol Trace Elem Res, 2010, 133(1), pp. 83-97).\*

Japanese Notification of Reasons for Refusal mailed by Japanese Patent Office dated Jan. 27, 2020 in corresponding Japanese patent application No. 2019-516717.

Li, Tan et al., Vitamin E and Se interfere in cytochrome P4501A1 and lipid peroxidation in nonalcoholic fatty liver, World Chinese Journal of Digestology, Oct. 8, 2007, vol. 15, No. 28, ISSN:1009-3079, p. 2977-2982.

Japanese Decision of Refusal mailed by Japanese Patent Office dated Apr. 13, 2020 in corresponding Japanese patent application No. 2019-516717

Chinese Notification of Reasons for Refusal mailed by Chinese Patent Office dated Nov. 11, 2020 in corresponding Chinese patent application No. 201780069336.5.

Haruko Sugino et al., Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis, Journal of Gastroenterology and Hepatology, vol. 23, p. 1909-1915.

Ma Na, Sodium selenite improves nonalcoholic fatty liver disease by reversing abnormal thyroid hormone transformation, Chinese excellent masters thesis collection (medical health science technology) issue02, p. 38.

Ashwani K. Signal et al., Antioxidants as therapeutic agents for liver disease, Liver International. 1432-1448.

\* cited by examiner

Primary Examiner — Kathrien A Cruz (74) Attorney, Agent, or Firm — IP Business Solutions, LLC

# (57) ABSTRACT

Provided is a method for treating non-alcoholic steatohepatitis (NASH), the method includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition and the pharmaceutical composition contains polaprezinc as zinc preparation and sodium selenite as selenium preparation.

1 Claim, 11 Drawing Sheets
(3 of 11 Drawing Sheet(s) Filed in Color)